Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

Immunoprecipitation

Immunoprecipitation

Immunoprecipitation, or IP, is a widely used technique that employs protein-antibody interactions to isolate proteins or protein complexes in their native state for studying protein-protein interactions, quaternary structures, or supramolecular complexes. Various modifications of the technique, including chromatin IP, cross-linking IP, and fluorescence IP, are commonly used.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation, also known as ChIP, is used to study protein-DNA or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effects of Dulaglutide on Thyroid C Cells and Serum Calcitonin in Male Monkeys.

Endocrinology·2015

Same author

Chronic Toxicity and Carcinogenicity Studies of the Long-Acting GLP-1 Receptor Agonist Dulaglutide in Rodents.

Endocrinology·2015

Same author

Fully human anti-BAFF inhibitory monoclonal antibody tabalumab does not adversely affect T-dependent antibody responses in cynomolgus monkey (Macaca fasicularis): A summary of three pre-clinical immunotoxicology evaluations.

Journal of immunotoxicology·2015

Same author

Nonclinical safety biomarkers of drug-induced vascular injury: current status and blueprint for the future.

Toxicologic pathology·2014

Same author

Developmental immunotoxicity (DIT) testing of pharmaceuticals: current practices, state of the science, knowledge gaps, and recommendations.

Journal of immunotoxicology·2012

Same author

A comparison of mortality and cardiac biomarker response between three outbred stocks of Sprague Dawley rats treated with isoproterenol.

Toxicologic pathology·2011

Search research articles

Related Experiment Video

Updated: Jun 28, 2026

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

Preclinical immunogenicity testing for recombinant therapeutic proteins.

Holly W Smith¹, Daniel Wierda

¹Eli Lilly & Company, Investigative Toxicology, Greenfield, Indiana 46140, USA. smith_holly_w@lilly.com

Journal of Immunotoxicology

|October 30, 2008

Summary

Assessing the immunogenicity of recombinant therapeutic proteins (RTPs) is crucial due to adverse events. A preclinical animal hyperimmunization model aids in evaluating RTP immunogenicity and potential adverse effects.

More Related Videos

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency

Published on: May 11, 2020

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

Related Experiment Videos

Last Updated: Jun 28, 2026

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency

Published on: May 11, 2020

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

Area of Science:

Biotechnology
Immunology
Pharmacology

Background:

Recombinant therapeutic proteins (RTPs) are increasingly scrutinized for immunogenicity.
Adverse clinical events in patients treated with RTPs necessitate re-evaluation of immunogenicity assessment methods.
Current methods require refinement to accurately predict the immunogenic potential of therapeutic proteins.

Purpose of the Study:

To highlight the growing importance of assessing RTP immunogenicity.
To introduce a preclinical animal hyperimmunization model for evaluating RTP immunogenicity.
To discuss key assay development parameters and techniques for measuring immune responses.

Main Methods:

Utilizing a comparative hyperimmunization technique in animals to optimize immunological response.
Employing the hyperimmunization model to analyze immunogenic potential and adverse effects of different RTP formulations.
Generating RTP-specific antisera from the model for assay technique selection and optimization.

Main Results:

The hyperimmunization model effectively optimizes immunological responses for assessing RTPs.
This model aids in analyzing the immunogenic potential and potential adverse effects of various RTP formulations.
Antisera generated can guide the selection of appropriate assay techniques and conditions.

Conclusions:

The preclinical animal hyperimmunization model is a valuable strategy for assessing the immunogenicity of recombinant therapeutic proteins.
This model aids in understanding potential adverse effects and selecting optimal assay techniques.
Continued focus on assay development parameters like affinity, washes, and sensitivity is essential for accurate immunogenicity assessment.